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AdjuvantPolio is on the brink of eradication. Improved inactivated polio vaccines (IPV) are needed towards com-
plete eradication and for the use in the period thereafter. Vaccination via mucosal surfaces has important
potential advantages over intramuscular injection using conventional needle and syringe, the currently
used delivery method for IPV. One of them is the ability to induce both serum and mucosal immune
responses: the latter may provide protection at the port of virus entry.
The current study evaluated the possibilities of polio vaccination via mucosal surfaces using IPV based
on attenuated Sabin strains. Mice received three immunizations with trivalent sIPV via intramuscular
injection, or via the intranasal or sublingual route. The need of an adjuvant for the mucosal routes was
investigated as well, by testing sIPV in combination with the mucosal adjuvant cholera toxin.
Both intranasal and sublingual sIPV immunization induced systemic polio-specific serum IgG in mice
that were functional as measured by poliovirus neutralization. Intranasal administration of sIPV plus
adjuvant induced significant higher systemic poliovirus type 3 neutralizing antibody titers than sIPV
delivered via the intramuscular route. Moreover, mucosal sIPV delivery elicited polio-specific IgA titers
at different mucosal sites (IgA in saliva, fecal extracts and intestinal tissue) and IgA-producing B-cells
in the spleen, where conventional intramuscular vaccination was unable to do so. However, it is likely
that a mucosal adjuvant is required for sublingual vaccination. Further research on polio vaccination
via sublingual mucosal route should include the search for safe and effective adjuvants, and the develop-
ment of novel oral dosage forms that improve antigen uptake by oral mucosa, thereby increasing vaccine
immunogenicity. This study indicates that both the intranasal and sublingual routes might be valuable
approaches for use in routine vaccination or outbreak control in the period after complete OPV cessation
and post-polio eradication.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the past decades, the global incidence of paralytic
poliomyelitis has decreased by more than 99% since 1988. Type 2
wild poliovirus was eradicated in 1999 and the last reported case
of type 3 wild poliovirus was from 2012. Since 2015, cases of type
1 wild poliovirus were only detected in the remaining endemic
countries (i.e., Pakistan, Afghanistan and Nigeria) [1]. It is expected
that wild poliovirus will be eradicated within a few years. How-
ever, to accomplish a polio-free world, eradication efforts should
focus on both wild polioviruses as well as vaccine-derived viruses.
Therefore, the endgame strategy of the Global Polio Eradication Ini-
tiative (GPEI) includes a phased withdrawal of the live-attenuatedoral polio vaccine (OPV), the source of vaccine-derived viruses, and
the worldwide inclusion of the inactivated polio vaccine (IPV) into
all routine immunization programs [2]. The GPEI is pursuing sev-
eral priority approaches for the development of a new generation
of IPV [3]. To this extent, Intravacc has developed a new polio vac-
cine based on Sabin polio viruses, Sabin IPV (sIPV), that is being
transferred to local vaccine manufacturers to support post-
eradication goals in terms of biosafety and IPV availability [4–7].
A new generation of sIPV should not only be affordable and safe
to produce, but preferably should also induce mucosal immunity,
remain stable, and be easy to administer. This is important with
regard to stockpiling and outbreak management in the period after
cessation of OPV and after eradication. Several alternative polio
vaccine delivery strategies are in development, with a focus on
dermal delivery of polio vaccines [8]. Vaccination via mucosal sites
has the benefits of needle free vaccine delivery. Moreover, mucosal
immunization is able to elicit strong mucosal immunity, even at
distant effector sites. As we know from OPV, polio-specific mucosal
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interruption of polio transmission [9].
The current study evaluated the potential of different mucosal
routes, i.e., intranasal and sublingual, in mice. It was investigated
whether intranasal or sublingual vaccination with sIPV is able to
elicit functional systemic immunity (serum) as well as local
immune responses at different mucosal sites.2. Materials and methods
2.1. Vaccine
Monovalent Sabin IPV bulk material used in this study was pro-
duced as described previously [10]. For the preparation of trivalent
sIPV, monovalent type 1, type 2 and type 3 were mixed and diluted
inM199medium (Bilthoven Biologicals, TheNetherlands) to a nom-
inal concentration of 1000–1600–3200 D-antigen units (DU) permL
for type 1, type 2 and type 3, respectively. Cholera toxin from Vibrio
Cholerae was purchased from Sigma-Aldrich (St. Louis, MO).
2.2. Immunization study
The animal experiment was performed according to the guide-
lines provided by the Dutch Animal Protection Act, and was
approved by the Committee of Animal Experimentation (DEC) of
the National Institute of Public Health and Environment (RIVM).
Balb/cOlaHsd mice (8–10 weeks old from Envigo, The Netherlands)
were anesthetized with ketamine-xylazine, and received a single
human dose (based on previous clinical studies [6,11]) trivalent
sIPV (10–16–32 DU/dose) via the intramuscular (IM, injection of
50 mL in hind limb), intranasal (IN, pipetting 10 mL in the nose) or
sublingual (SL, pipetting 10 mL under the tongue) route at day 0,
7 and 28. Adjuvanted groups received 5 mg/dose cholera toxin.
Upon SL immunization, mice were maintained in upright position
to minimize the risk of swallowing. Blood samples were taken at
day 0 (prior to immunization) and day 14 (after second immuniza-
tion). At day 35, anesthetized animals received an intraperitoneal
injection of 0.1 mL of 0.05 M pilocarpine (Sigma-Aldrich, St. Louis,
MO) in PBS to induce saliva production. Saliva was collected and,
subsequently, animals were sacrificed by bleeding. Post-mortem,
fecal samples were isolated from the large intestine, weighted
and stored at 80 C until analysis. Spleens were placed in RPMI-
1640 medium (Gibco, Invitrogen) supplemented with 5% fetal
bovine serum and placed on ice for the B-cell ELISPOT. Small
intestines were harvested and placed in 3 mL PBS containing
50 mM EDTA (Gibco, Invitrogen) and protease inhibitors (Com-
plete, Mini, EDTA free, Roche Applied Sciences). Small intestines
were extensively vortexed and centrifuged for 15 min at 300g
(4 C). Supernatants, mentioned further as intestinal wash, were
collected and stored at 80 C until analysis (IgA ELISA). Subse-
quently, small intestines were cut into small pieces, transferred
to cryotubes, and 2 mL PBS containing 2% saponin (Sigma Aldrich,
St. Louis, MO) and protease inhibitors was added per mg intestinal
sample. After a fast freezing step, samples were centrifuged for
20 min at 4600 rpm and supernatants were filtered through
0.22 mm filters (Merck Millipore, Darmstadt, Germany). Intestinal
tissue samples were stored at 80 C until further analysis. The
presence of both excreted (intestinal washes) and intracellular
(intestinal tissue samples) polio-specific IgA in small intestine
was assessed by ELISA.
2.3. IgG and IgA ELISA
Enzyme linked immunosorbent assays (ELISA) were performed
to determine polio-specific antibody titers in sera, saliva, feces,intestinal washes and intestinal tissue samples. Fecal extracts were
prepared by adding fecal extract buffer, PBS containing 10% normal
goat serum (Sigma Aldrich, St. Louis, MO) and protease inhibitors,
to the fecal pellets (0.2 g/mL). Fecal extracts were extensively vor-
texed and, subsequently, centrifuged for 15 min at 13,000 g. Super-
natants were filtered through 0.22 mm filters and immediately
tested. For the ELISA, polystyrene 96 wells microtiter plates (Grei-
ner Bio-One, Alphen a/d Rijn, The Netherlands) were coated over-
night at 4 C with bovine anti-poliovirus serum (Bilthoven
Biologicals, Bilthoven, The Netherlands) in PBS (Gibco from Invitro-
gen, Paisley, UK). After washing coated plates with 0.05% (v/v)
Tween 80 (Merck, Darmstadt, Germany) in tap water, trivalent
inactivated polio vaccine diluted in assay buffer, PBS containing
0.5% (w/v) Protifar (Nutricia, Zoetermeer, The Netherlands) and
0.05% (v/v) Tween 80 (Merck, Darmstadt, Germany), was added
and incubated for 2 h at 37 C. Subsequently, plates were washed
and threefold sample dilutions in assay buffer were added and
incubated for another 2 h at 37 C. After washing, plates were incu-
bated with horse-radish peroxidase (HRP)-conjugated goat-anti-
mouse IgG or HRP-conjugated goat-anti-mouse IgA (Southern Bio-
tech, Birmingham, AL). After 1 h incubation at 37 C, plates were
washed and TMB substrate solution, containing 1.1 M sodium acet-
ate (Bilthoven Biologicals, Bilthoven, The Netherlands), 100 mg/mL
3,30,5,50-tetramethylbenzidine (Sigma-Aldrich, St. Louis, MO), and
0.006% (v/v) hydrogen peroxide (Merck, Darmstadt, Germany),
was added to each well. After 10–15 min., the reaction was stopped
with 2 M sulfuric acid (Bilthoven Biologicals, Bilthoven, The
Netherlands) and absorbance was measured at 450 nm by using
a Biotek L808 plate reader. For the CT-specific ELISA, plates were
coated with 1 mg/mL CT and blocked with 1% Protifar in PBS. ELISA
was further performed as described above. Endpoint titers were
determined by 4-parameter analysis using the Gen5TM 2.0 Data
Analysis software (BioTek Instruments, Inc., Winooski, VT) and
defined as the reciprocal of the serum dilution producing a signal
identical to that of negative control samples at the same dilution
plus three times the standard deviation.
2.4. Virus neutralization (VN) assay
Neutralizing antibodies against all three poliovirus types were
measured separately by inoculating Vero cells with 100 TCID50 of
the wild-type strains (Mahoney, MEF-1 and Saukett) as described
previously [12,13]. Twofold serial serum dilutions were made
and serum/virus mixtures were incubated for three hours at
36 C and 5% CO2 followed by overnight incubation at 5 C. Subse-
quently, Vero cells were added and after 7 days of incubation at
36 C and 5% CO2, the plates were stained and fixed with crystal
violet and results were read macroscopically. Virus neutralizing
(VN) titers were expressed as the last serum dilution that has an
intact monolayer (no signs of cytopathogenic effect).
2.5. B-cell ELISPOT
MultiScreen-HTS IP 96 wells filter plates (Merck Millipore,
Darmstadt, Germany) were wet by adding 35% ethanol, immedi-
ately washed twice with PBS and, subsequently, coated overnight
with 5 mg/mL monovalent IPV type 1, 2 or 3. As a positive control,
wells were coated with a mixture of 7 mg/mL purified goat-anti-
mouse kappa and 7 mg/mL purified goat-anti-mouse lambda
(Southern Biotech). As a negative control, wells were left uncoated
(PBS). After washing with PBS, plates were blocked with RPMI-
1640 medium (Gibco, Invitrogen) with 2% Protifar (Nutricia,
Zoetermeer, The Netherlands) for 1 hour at room temperature.
Spleens were homogenized using a 70-mm cell strainer (BD Falcon,
BD Biosciences) and cells were collected in RPMI-1640 supple-
mented with 10% fetal bovine serum and antibiotics (Penicillin-St
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were removed by ACK lysis buffer (Gibco, Invitrogen). After wash-
ing, cells were counted and 5  105 cells/well were added to coated
plates. After overnight incubation at 37 C and 5% CO2 plates were
washed extensively and wells were developed by stepwise incuba-
tions with AP-conjugated goat-anti-mouse IgA (Southern Biotech)
and washing with PBS followed by the addition of BCIP-NBT liquid
substrate (Sigma Aldrich, St. Louis, MO). Plates were kept in dark
during spot development and thereafter, the reaction was stopped
by discarding the substrate and extensively washing of both sides
of the filter with tap water. Plates were dried overnight at 37 C
and spots were counted using EliSpot reader (AID iSpot FluoroSpot
Reader System, Autoimmun Diagnostika GmbH, Strassberg, Ger-
many) and AID EliSpot software.
2.6. Statistical analysis
Data was statistically analyzed by comparing all groups by a
Kruskal-Wallis test followed by a Dunn’s multiple comparisons
test. Probability (p) values of p < 0.05 were considered statistically
significant. Statistics were performed using GraphPad Prism ver-
sion 6.07 (GraphPad Software Inc., La Jolla, CA).
3. Results
3.1. Systemic immunity elicited after mucosal sIPV administration
To assess whether systemic immunity was induced after vacci-
nation of mice with sIPV via conventional intramuscular (IM) injec-
tion, via the nose (intranasal, IN), or under the tongue (sublingual,
SL), polio-specific IgG antibodies were measured in serum. For both+
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Fig. 1. Systemic immunity induced after vaccination with sIPV via parenteral or muco
immunized with sIPV via conventional intramuscular (IM, circles) injection or via sub
vaccinations were given in the absence (black symbols) or presence (blue symbols) of the
(day 14, panel A) and third immunization (day 35, panel B). Mean values were depicted
indicate significant differences between groups (*p < 0.05, **p < 0.01, ***p < 0.001).mucosal routes (SL and IN), the vaccine was also given in the pres-
ence of cholera toxin (CT), which is known as a strong mucosal
adjuvant [14–16]. Prior to immunization, no polio-specific immune
responses were detected (data not shown). After two immuniza-
tions (day 14), evident polio-specific IgG antibody titers were
already induced in the group of mice vaccinated with sIPV via
the conventional intramuscular route using needle and syringe
(Fig. 1A). Intranasal and sublingual administered sIPV without
adjuvant induced significantly lower anti-polio type 1 IgG titers
than the intramuscular control group (respectively, p < 0.05 and
p < 0.001) (Fig. 1A and B). However, the inclusion of CT as adjuvant
significantly improved systemic IgG responses after intranasal sIPV
vaccination. Animals that received sIPV plus CT via the intranasal
route induced polio-specific IgG antibody titers similar to those
obtained after intramuscular vaccination, both at day 14 (2 immu-
nizations) (Fig. 1A) and day 35 (3 immunizations) (Fig. 1B). For the
sublingual route, higher numbers of responders were observed
after immunization with sIPV plus CT with a significant enhanced
IgG antibody titers against polio type 3 induced after 2 immuniza-
tions (day 14) (Fig. 1A). For the induction of detectable systemic
IgG after sublingual sIPV delivery, an adjuvant (Fig. 1A) and/or at
least 3 vaccinations were needed (Fig. 1B).
To investigate the functionality, the virus-neutralizing capacity
of the sera was determined after three immunizations. All mice
from the intramuscular control group showed distinct neutralizing
antibody titers against all three poliovirus types (Fig. 2). The pres-
ence of CT adjuvant was beneficial for the induction of virus-
neutralizing antibodies after sIPV vaccination via the sublingual
or intranasal route. For all serotypes higher numbers of animals
responded after mucosal sIPV immunization plus CT (Fig. 2).
Besides, significantly higher virus-neutralizing (VN) titers were+
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Fig. 2. Virus-neutralizing capacity of serum from mice immunized with sIPV via parenteral or mucosal routes. Virus-neutralizing (VN) serum antibody titers were measured
from mice (n = 8) immunized three times with sIPV via conventional intramuscular (IM) injection or via sublingual (SL) or intranasal (IN) route. For both mucosal routes,
vaccinations were given in the absence (black symbols) or presence (blue symbols) of the mucosal adjuvant cholera toxin (CT). Sera were collected one week after the third
immunization (day 35). Mean VN titers were depicted as horizontal line and error bars showed 95% confidence interval values. Asterisks indicate significant differences
between groups (*p < 0.05, **p < 0.01). Hashtags indicate a significant difference with the conventional IM group (#p < 0.05).
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Fig. 3. Systemic antibody titers induced against cholera toxin (CT) delivered via
sublingual or intranasal routes. CT-specific IgG antibody titers were measured in
serum from mice (n = 8) immunized with sIPV plus CT as adjuvant via sublingual or
intranasal route. Sera were collected one week after the third immunization (day
35). Individual (blue symbols) and mean (bars) were depicted. Error bars represent
95% confidence interval values. Mean values differ significantly (p = 0.0093) as
2650 H. Kraan et al. / Vaccine 35 (2017) 2647–2653induced after intranasal vaccination of sIPV plus CT compared to
intranasal vaccination in the absence of an adjuvant, both for type
1 (p < 0.05) and type 3 (p < 0.05). Similar VN titers were obtained
after sublingual vaccination in the presence of an adjuvant com-
pared to conventional intramuscular immunization (without adju-
vant), although some non-responders were observed after
sublingual vaccination (Fig. 2). Interestingly, superior type 3-
specific VN titers were observed after sIPV (plus adjuvant) delivery
via the nose, even when compared to intramuscular injected sIPV
(p < 0.05) (Fig. 2).
To evaluate whether differences in systemic immune responses
could be assigned to a difference in antigen penetration through
and uptake by mucosae, antibody titers against the adjuvant, the
highly immunogenic cholera toxin (CT), were measured in sera
from mice that received sIPV plus CT. After three immunizations,
all animals induced evident CT-specific IgG antibody titers
(Fig. 3). Even after vaccination via the sublingual route, no non-
responders were observed, whereas in some animals no detectable
polio-specific IgG titers were found (Fig. 1). Significantly improved
IgG antibody titers against CT were observed after intranasal vac-
cination compared with those obtained after sublingual immuniza-
tion (p < 0.01) (Fig. 3).analyzed by Mann-Whitney test.3.2. Mucosal immune responses induced after SL and IN immunization
with sIPV
Polio-specific IgA antibody endpoint titers were determined in
different mucosal samples to evaluate mucosal immunity after
sIPV immunization of previously mentioned administration routes.
Both sublingual and intranasal administration of sIPV induced
polio-specific IgA antibody responses in saliva (Fig. 4A) and feces
(Fig. 4B), whereas the intramuscular route was unable to do so.
Non-adjuvated sIPV delivery via the sublingual route induced no
detectable salivary IgA against polio type 1 and 2, and no polio-
specific fecal IgA (Fig. 4A and B). Sublingual vaccination of sIPV
in combination with CT resulted in higher numbers of mice having
detectable IgA titers in mucosal samples. For type 3, significant
salivary IgA titers were elicited after sublingual administration of
sIPV plus CT (Fig. 4A). Also significantly enhanced polio-specific
IgA titers (all serotypes) were observed in mice immunized intra-
nasally with sIPV plus CT, both in saliva (p < 0.001) and feces
(p < 0.001) (Fig. 4A and B).
To evaluate the intestinal immune responses further, local IgA
antibody production was determined by ELISA on detergent
extractions of small intestinal samples. No intestinal immunitywas induced after intramuscular vaccination with sIPV. Only for
type 3, 25% of the animals induced polio-specific IgA in the intes-
tine after sublingual delivery of sIPV, with or without adjuvant
(Fig. 4C). Again, animals immunized via the intranasal route with
sIPV plus CT showed significantly improved IgA antibodies against
polio type 1 (p < 0.001), type 2 (p < 0.05) and type 3 (p < 0.001)
(Fig. 4C).3.3. Polio-specific B cell responses elicited after SL and IN
immunization with sIPV
The effect of the different immunization routes on the numbers
of polio-specific plasma cells was evaluated in single cell suspen-
sions from spleens. Whereas no IgA-secreting plasma cell
responses were found in splenocytes from mice immunized via
intramuscular injection, significantly enhanced numbers of IgA-
producing B-cells were found in spleens of mice immunized via
the intranasal route with either unadjuvanted sIPV (type 2
(p < 0.05); type 3 (p < 0.01)) or CT-adjuvanted sIPV (type 1
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presence of CT enhanced the B cell responses after sublingual
delivery of sIPV, since a higher number of animals showed IgA-
producing B cell responses compared to the unadjuvanted sublin-
gual group. Moreover, mice vaccinated sublingually with sIPV plus
CT showed significantly enhanced numbers of polio type 2-specific
IgA-secreting B cells (p < 0.01) (Fig. 5).4. Discussion
The goal of the current study was to evaluate whether mucosal
administration of sIPV could elicit both systemic immunity and
polio-specific mucosal IgA at distinct mucosal sites. sIPV deliveredvia the sublingual or intranasal route was able to induce systemic
polio-specific IgG responses with poliovirus-neutralizing capacity.
Besides, mucosal vaccination of sIPV elicited polio-specific IgA
antibody titers at distinct mucosal sites including strong intestinal
responses after IN immunization and IgA-producing B cell
responses in the spleen both after IN and SL immunization.
Mucosal compartmentalization restricts the induction of
intestinal immunity upon intranasal immunization [17,18]. The
existing paradigm that only gut-resident dendritic cells (DCs) can
recruit T cells to the gastrointestinal tract is difficult to reconcile
with our findings and other reports of gastrointestinal T cell
responses and protective gut immunity after intranasal immuniza-
tion of influenza [19,20] or Salmonella antigen [21]. Ruane et al.
showed that lung DCs, which were targeted by intranasal
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CD4+ T cells in the lungs, and induced cell migration to the gas-
trointestinal tract in mice [22]. Therefore, it might be that intrana-
sal vaccine delivery is able to recruit antigen-specific immune cells
to the gut and thereby inducing local intestinal immunity, which is
in agreement with our findings.
Mucosal vaccine delivery has several practical advantages over
vaccination via parenteral routes using needle and syringes, as
previously mentioned. However, only relatively few mucosal vac-
cines for human use are licensed [23]. With the exception of some
cholera vaccines, which have a very strong intrinsic immune
potentiating capacity [24], all these mucosal vaccines are live
attenuated vaccines, like OPV or intranasal influenza vaccines
(Flumist/Fluenz) [8,25]. In contrast to OPV, mucosal polio vaccina-
tion based on IPV is expected to require the inclusion of an adju-
vant to evoke appropriate immunity against polio [13], which was
confirmed in the current preclinical study. Both intranasal and
sublingual vaccination of sIPV plus cholera toxin (CT) as adjuvant
were able to significantly enhance functional systemic immunity
and polio-specific IgA titers in mucosal samples compared to
immune responses obtained after mucosal sIPV vaccination with-
out adjuvant. However, CT and the Escherichia coli-derived heat-
labile toxin (LT) are well known as potent mucosal adjuvants,
but are also associated with adverse effects in humans. Concerns
has been raised after an undesired association between facial
nerve paralysis (Bell’s palsy) and the intranasally delivered inacti-
vated influenza vaccine (Nasalflu) containing an enzymatically
active LT adjuvant [26]. Probably the neuronal-binding capacity
of the LT-derived adjuvant was the cause of this adverse effect
suggesting that nasal administration of LT or CT molecules is inad-
visable [27]. Migration to or accumulation in the central nerve
system might be avoided by vaccine administration under the
tongue [28–30]. Moreover, in a recent Phase 1 study
(NCT00820144) conducted in France, the sublingual administra-
tion of recombinant CT B subunit in healthy subjects was found
to be safe. Therefore, a new safe mucosal adjuvant with strong
immune potentiating capacity should be included in the further
development of a mucosal (Sabin) IPV although adverse effects
after sublingual immunization are not documented as far as we
know. Since the mucosal route is minimally addressed for IPV
yet, current experience is limited to the use of a double mutant
of LT (dmLT) in combination with the sublingual route as
described by White et al. [31]. Adjuvants (e.g., LPS derivative PagL,
oil-in-water emulsions, CpG ODN) that have shown their potential
for (Sabin) IPV via the parenteral route could also be evaluated for
mucosal vaccination [12,32].In the last decade, sublingual vaccine delivery has gained signif-
icant attention as shown by the numerous published preclinical
studies that provide a strong base for further testing of this non-
invasive route [33]. Our findings and earlier research indicates that
the inclusion of an adjuvant might be needed to avoid tolerance or
low-to-undetectable immune responses after sublingual delivery
of IPV [31]. Besides the inclusion of an adjuvant as immune poten-
tiator, novel oral dosage forms to improve contact time or to facil-
itate transport through the mucosal barrier, may be required to
achieve successful vaccination. White et al. studied the sublingual
route for IPV (based on Salk strains) using a thermoresponsive gel
(TRG) delivery system [31]. Whereas sublingual administration of
IPV as a liquid or as TRG in the absence of an adjuvant was not able
to induce any immune response in mice, sublingual administered
IPV as TRG in combination with the mucosal adjuvant dmLT led
to systemic poliovirus-neutralizing antibody titers, and salivary
and fecal IgA production [31]. A comparison between the liquid
and TRG formulation (both with or without adjuvant) is missing,
but it is expected that mucoadhesive dosage forms that prolong
the residence time of the vaccine at the oral mucosa and thereby
facilitate antigen uptake by local antigen-presenting cells, are
needed [13,33]. Research on sublingual polio vaccination may,
besides the use of novel adjuvants, comprise development of
extended release formulations, including solid dosage forms that
at the same time improve the thermostability of the vaccine as
well. Earlier studies revealed that dried IPV can be more resistant
to higher temperatures compared to liquid IPV [34–36].
The phased withdrawal of OPV and inclusion of IPV into all glo-
bal routine immunization programs will create a market for non-
invasive delivery of polio vaccines, even a considerable time after
eradication either for routine immunization or stock piling.
Improved polio vaccine delivery strategies should be suitable for
the final target population: infants. The current study demon-
strated the potential of both the intranasal and sublingual routes
for polio vaccination with IPV based on Sabin strains. Intranasal
vaccination showed to be more efficient in eliciting both systemic
and mucosal immune responses compared with the sublingual
route. However, besides possible redirection to olfactory bulbs
(Bell’s palsy), the risk of wheezing in young children exists [8].
The sublingual route could be an easy and safe polio immunization
approach. Nevertheless, for the induction of evident immunity
upon sIPV vaccination under the tongue, strong mucosal adjuvants
might be required. Therefore, further research on polio vaccination
via the sublingual route should include the search for a safe and
effective adjuvant and the development of novel oral dosage forms
that improve antigen uptake by the oral mucosa.
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